Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology · POEMS Syndrome

Recovery and Long-Term Monitoring

At a Glance

POEMS syndrome recovery is tracked across five areas: VEGF and blood markers, symptoms and organ changes, nerve function, and imaging. VEGF may improve within months, but nerve recovery can take up to three years, making regular follow-up and rehabilitation important.

Recovery from POEMS syndrome is not a single event, but a series of improvements across different “domains” of your health. Because the disease affects so many systems, your doctors will track your progress using several different yardsticks. Understanding the timeline of these changes can help you set realistic expectations for your healing journey [1][2].

The Five Domains of Recovery

Your care team will monitor five specific areas to ensure the treatment is working and the disease is in remission:

  1. VEGF Response: This is usually the first sign of improvement. Vascular Endothelial Growth Factor levels often begin to drop within 1 to 2 months of starting treatment [3]. Normalization of VEGF by the 6-month mark (with exact target levels depending on the lab assay used) was associated with better long-term outcomes in specific study cohorts [4][5]. It is critical that the same validated assay is used for serial monitoring.
  2. Hematologic Response: This measures the “source”—the abnormal plasma cell clone. Doctors look for the disappearance of the M-protein or lambda light chains in your blood and urine [6]. This response often takes longer than the VEGF drop, which can sometimes take many months to achieve [7][8].
  3. Clinical Response: This includes the resolution of systemic symptoms. Fluid buildup (edema and ascites) and organ enlargement often begin to improve within the first 3 to 6 months [9][10]. Skin changes, like darkening or hair growth, may take up to 12 months to fully resolve [3].
  4. Neurologic Response: This is the slowest domain to recover. While you may feel stronger within a few months, nerves heal at a very slow pace [11]. It can take up to 3 years to achieve the maximal improvement in your strength and sensation [12].
  5. Radiologic Response: Doctors will use follow-up CT or PET scans to ensure your sclerotic bone lesions are stable and that any enlarged organs have returned to a normal size [1][6]. Sclerotic bone lesions often remain visible on scans despite disease control; stability rather than disappearance is tracked [6].

Tracking Your Physical Progress

To measure your neurologic recovery objectively, your doctor will likely use the Overall Neuropathy Limitation Scale (ONLS). This scale scores your ability to use your arms and legs on a scale of 0 (no limitation) to 12 (maximal limitation) [13].

  • The 1-Year Landmark: The ONLS is one optional functional measure; while a 3-point improvement is a positive sign in some cohorts, interpreting this change is highly individualized [8].
  • Physical Therapy: Because the nerves take so long to heal, staying committed to physical therapy is essential for years, not just months. This prevents your joints from becoming stiff and helps your brain “re-learn” how to use muscles as the nerves slowly reconnect [14]. Supportive care remains vital during this time, including pain treatment, fall prevention, orthotics, safe exercise, edema care, and vaccinations [15].

Long-Term Monitoring and Survivorship

Even after you achieve remission, long-term surveillance is necessary because different parts of the disease can return at different times [2].

  • Prognostic Factors: Your doctors will pay close attention to your kidney function (eGFR) and your lung health. Severe kidney impairment or the presence of pulmonary hypertension (high blood pressure in the lungs) at diagnosis are important factors that require ongoing, careful monitoring [16][17].
  • Scan Anxiety: It is normal to feel anxious before follow-up blood tests or imaging. Remember that a slight rise in VEGF isn’t always a sign of relapse—things like a recent flu or infection can temporarily bump your levels [18]. Your doctor will look at the “big picture” across all five domains rather than reacting to a single lab value [19].
  • The Relapse Timeline: If POEMS does return, it can present in different ways; in one specific cohort, VEGF levels rose first at a median of 35 months, followed by clinical symptoms at 48 months, and the M-protein at 72 months [2]. This is a cohort observation, not a universal rule. This is why regular blood work is your best early-warning system.

By staying engaged with your multidisciplinary team and maintaining your rehabilitation routine, you can maximize your recovery and protect your health for the years to come [15].

Common questions in this guide

What are doctors looking for during POEMS syndrome recovery?
Doctors usually track five areas: VEGF, blood markers from the plasma cell disorder, symptoms and organ changes, nerve function, and imaging. Improvement in one area may occur before another, so recovery and remission are judged from the overall pattern rather than a single result.
How quickly should VEGF fall after POEMS treatment?
VEGF often starts falling within 1 to 2 months. The normalization target depends on the laboratory assay, so serial tests should use the same validated assay and be interpreted alongside symptoms, blood markers, and other findings.
How long does nerve damage take to improve in POEMS syndrome?
Neurologic recovery is often slow, and strength and sensation may continue to improve for up to three years. Physical therapy, safe exercise, pain management, fall prevention, and orthotics can support function while the nerves heal.
Can bone lesions still be seen after POEMS syndrome is controlled?
Yes. Sclerotic bone lesions may remain visible on CT or PET even when the disease is controlled, so doctors often focus on whether the lesions are stable rather than whether they have disappeared. Imaging is considered together with blood tests and clinical changes.
What follow-up tests are needed after POEMS remission?
Long-term follow-up may include VEGF, M-protein or lambda light-chain testing, kidney function such as eGFR, lung or pulmonary artery pressure monitoring, and CT or PET imaging when indicated. Your team may also track symptoms, neurologic function, and physical abilities.
Does a small VEGF increase always mean POEMS syndrome has returned?
No. An infection or recent flu can temporarily raise VEGF, and a single result does not establish relapse. Doctors look for a consistent pattern across laboratory results, symptoms, neurologic function, and imaging.
What does an ONLS score tell me about POEMS recovery?
The Overall Neuropathy Limitation Scale rates how much neuropathy limits arm and leg function, from 0, meaning no limitation, to 12, meaning maximum limitation. A change over time can show functional progress, but clinicians interpret it alongside strength, sensation, and daily activities.

Get notified when new evidence is published on Polyendocrine-polyneuropathy syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Comprehensive Diagnosis and Management of POEMS Syndrome.

    D'Sa S, Khwaja J, Keddie S, et al.

    HemaSphere 2022; (6(11)):e796 doi:10.1097/HS9.0000000000000796.

    PMID: 36340912
  2. 2

    Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment.

    Kourelis TV, Buadi FK, Gertz MA, et al.

    Leukemia 2016; (30(5)):1079-85 doi:10.1038/leu.2015.344.

    PMID: 26669974
  3. 3

    A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.

    Li J, Huang XF, Cai QQ, et al.

    American journal of hematology 2018; (93(6)):803-809 doi:10.1002/ajh.25100.

    PMID: 29603764
  4. 4

    Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.

    Misawa S, Sato Y, Katayama K, et al.

    BMJ open 2015; (5(11)):e009157 doi:10.1136/bmjopen-2015-009157.

    PMID: 26560063
  5. 5

    Regular assessment of serum vascular endothelial growth factor levels to monitor POEMS syndrome.

    Gentile F, Terenghi F, Doneddu PE, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2024; (45(2)):727-733 doi:10.1007/s10072-023-07064-5.

    PMID: 37702830
  6. 6

    Pachymeningeal Involvement in POEMS Syndrome: Longitudinal Follow-Up Study and Correlation With Therapeutic Response.

    Briani C, Massarotti L, Branca A, et al.

    Journal of the peripheral nervous system : JPNS 2026; (31(1)):e70098 doi:10.1111/jns.70098.

    PMID: 41578669
  7. 7

    Detection of M-protein by iMS-IP and iMS-FLC assays redefines previously non-secretory POEMS syndrome.

    Huang Y, Li A, Yang Z, et al.

    Clinical chemistry and laboratory medicine 2026; (64(11)):2556-2563 doi:10.1515/cclm-2026-0489.

    PMID: 42420755
  8. 8

    Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients.

    Fang F, Lan XX, Hu RH, et al.

    Therapeutic advances in neurological disorders 2024; (17()):17562864231219151 doi:10.1177/17562864231219151.

    PMID: 38288324
  9. 9

    Diagnostic Challenges of Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, and Skin Changes (POEMS) Syndrome: A Rare Case Report and Review of the Literature.

    Kumar K, Daga R, Singh J, et al.

    Cardiovascular & hematological disorders drug targets 2025; (25(2)):133-138 doi:10.2174/011871529X352283250305042317.

    PMID: 40143390
  10. 10

    Skin Responses in Newly Diagnosed Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome After Therapy With Low-Dose Lenalidomide Plus Dexamethasone.

    Gao Y, Zhang S, Yang L, et al.

    Frontiers in immunology 2021; (12()):681360 doi:10.3389/fimmu.2021.681360.

    PMID: 34025681
  11. 11

    Development of Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome after Conversion from Plasmacytoma of Bone to Multiple Myeloma.

    Hatano K, Orimo K, Ogura M, et al.

    Internal medicine (Tokyo, Japan) 2023; (62(3)):475-479 doi:10.2169/internalmedicine.9101-21.

    PMID: 35831107
  12. 12

    Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review.

    Khouri J, Nakashima M, Wong S

    JAMA oncology 2021; (7(9)):1383-1391 doi:10.1001/jamaoncol.2021.0586.

    PMID: 34081097
  13. 13

    Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study.

    Keddie S, Foldes D, Caimari F, et al.

    Neurology 2020; (95(3)):e268-e279 doi:10.1212/WNL.0000000000009940.

    PMID: 32606227
  14. 14

    Living with Polyneuropathy Organomegaly Endocrinopathy Monoclonal gammopathy Skin changes (POEMS) syndrome: a case study of healthcare experiences and quality of life.

    Twigg J, Methley A, Lavin T, et al.

    Disability and rehabilitation 2021; (43(17)):2502-2510 doi:10.1080/09638288.2019.1700563.

    PMID: 31838877
  15. 15

    POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.

    Dispenzieri A

    American journal of hematology 2019; (94(7)):812-827 doi:10.1002/ajh.25495.

    PMID: 31012139
  16. 16

    Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome.

    Wang C, Huang XF, Cai QQ, et al.

    Leukemia 2017; (31(1)):100-106 doi:10.1038/leu.2016.168.

    PMID: 27338259
  17. 17

    Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: incidence, treatment and outcome.

    Ye W, Wang C, Cai QQ, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(2)):275-83 doi:10.1093/ndt/gfv261.

    PMID: 26130736
  18. 18

    Dramatically elevated plasma vascular endothelial growth factor levels from influenza A infection in polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome: A case report.

    Kannan A, Zhuo Y, Banerjee R

    EJHaem 2024; (5(4)):842-844 doi:10.1002/jha2.965.

    PMID: 39157604
  19. 19

    Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome.

    Pihan M, Keddie S, D'Sa S, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2018; (5(5)):e486 doi:10.1212/NXI.0000000000000486.

    PMID: 30175160

This page is for informational purposes only and does not constitute medical advice. Your hematology, neurology, and rehabilitation team should interpret your results and set your monitoring plan.

Guide contents Polyendocrine-polyneuropathy syndrome
Research & Literature
05 Building Your Care Team